Altria Group (NYSE:MO) CFO Billy Gifford says the tobacco producer is bullish on its investment in Ontario-based Cronos Group (NASDAQ:CRON,TSX:CRON).

During an earnings call with investors and analysts on Thursday (October 31), Gifford said Cronos is making strides with its growth strategy in the active cannabis space.

The executive pointed to Cronos’ recent acquisition of Redwood Holding Group as a beneficial move towards the cannabis company’s goal of establishing itself in the US cannabidiol (CBD) sector.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

As a part of the deal, Cronos is getting hold of the Lord Jones line of CBD-infused skincare products.

“We believe the acquisition fits well into Cronos’ strategy of building differentiated brands and disruptive intellectual property,” said Gifford. “We’re very excited about the future prospects of the cannabis industry and the opportunity for Cronos to position itself for long-term leadership.”

The Redwood Holding Group deal was valued at US$300 million, with US$225 million in cash and the balance paid in Cronos common shares.

Altria originally invested in Cronos back in 2018 after pumping US$1.8 billion into the cannabis firm. The company now has a 45 percent ownership stake, making it Cronos’ largest shareholder.

In its Q3 results, released on Thursday, Altria reported mark-to-market losses of US$636 million on Cronos-related financial instruments to buy more shares of the company. The cost was offset by US$87 million from Altria’s share of Cronos’ non-cash change in the fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares.

For the second quarter, Cronos reported net revenue of C$10.2 million, up 202 percent from the same quarter last year. Cronos also noted C$2.4 billion in proceeds from Altria’s investment in Q2.

Aside from its Cronos investment, Altria has cut the value of its stake in e-cigarette company JUUL by US$4.5 billion amid a vape health crisis in the US that has hit the cigarette and cannabis industries alike.

Altria said the factors that weighed on its decision to slash its stake in JUUL include an increased likelihood that the US Food and Drug Administration will decide to pull flavored e-vapor products from the market, as well as vape bans across the country. The deal was originally valued at US$12.8 billion in 2018, representing 35 percent ownership.

Share prices for both Altria and Cronos fluctuated during the trading day on Thursday.

Altria fell 2.6 percent in New York and sat at US$44.90 as of 2:50 p.m. EDT. Cronos dipped 1.4 percent from an opening price of C$10.88 to C$10.73 by 2:40 p.m. EDT.

Year-to-date, Cronos shares have been hit with a 30.3 percent decrease in value.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less